8-K: Moleculin Biotech Advances Annamycin to Phase 3 Trial for AML Treatment Following Positive FDA Meeting

Moleculin Biotech has announced plans to proceed with a Phase 3 clinical trial for Annamycin in combination with cytarabine for relapsed or refractory AML, following a positive meeting with the FDA.

Summary

• Moleculin Biotech has received positive feedback from the FDA regarding their End of Phase 1B/2 meeting for Annamycin.
• The company is now planning a Phase 3 pivotal trial called MIRACLE to evaluate Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML.
• The MIRACLE trial will be a global study, including sites in the US, and will use an adaptive design.
• The primary endpoint of the trial will be complete remission (CR) at day 30, compared to a placebo control group.
• The trial will initially focus on 2nd line treatment for R/R AML, followed by 3rd line treatment.
• The first 75 patients will be randomized to receive either HiDAC plus placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• After the first 75 patients, the trial will be unblinded to select the optimal dose of Annamycin.
• The second half of the trial will involve approximately 120 additional patients randomized to receive either HiDAC plus placebo or HiDAC plus the optimal dose of Annamycin.
• The company plans to submit a new drug application (NDA) for accelerated approval based on the primary endpoint of CR from the MIRACLE trial.
• The company also plans a follow-on MIRACLE2 trial in 3rd line patients once the optimal dose is established in the MIRACLE trial.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the positive FDA feedback, advancement to Phase 3, and confidence in the drug's efficacy. The company is also addressing the issue of lifetime maximum allowable dose for anthracyclines, which is a common limitation in cancer treatment.

Positives

• The FDA has provided valuable input and has de-risked the pathway to approval for Annamycin.
• The adaptive design of the MIRACLE trial allows for the selection of the optimal dose of Annamycin.
• The primary endpoint of CR at day 30 provides an opportunity for accelerated approval.
• The company is confident that Annamycin will meet the primary endpoint.
• The company plans to use the trial for approval in Europe.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML.
• Annamycin has Orphan Drug Designation from the EMA for the treatment of relapsed or refractory AML.

Risks

• The MIRACLE study is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents.
• All interim and preliminary data related to its active clinical trials are subject to change until a clinical study report is published.
• The company's expectations may prove to have been materially different from the results expressed or implied by forward-looking statements.

Future Outlook

The company plans to submit a new drug application (NDA) for accelerated approval based on the primary endpoint of CR from the MIRACLE trial and also plans a follow-on MIRACLE2 trial in 3rd line patients once the optimal dose is established in the MIRACLE trial.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that they are now able to finalize plans for a pivotal approval pathway in AML.
• Mr. Klemp also stated that the adaptive Phase 3 trial will rely solely on CR at day 30 as the primary endpoint versus placebo.
• Mr. Klemp believes that the planned pivotal trial should be able to generate data supportive of a true value inflection point for shareholders in a timely manner.
• Mr. Klemp concluded that the company is making the leap into being a Phase 3 company and that their planned approval is based on a primary endpoint comparing to a control that they are optimistic they can beat.

Industry Context

This announcement is significant as it moves Annamycin closer to potential market approval for AML, a disease with high unmet medical need. The use of an adaptive trial design and a primary endpoint of CR at day 30 are strategies that could accelerate the approval process. The company is also addressing the issue of lifetime maximum allowable dose for anthracyclines, which is a common limitation in cancer treatment.

Comparison to Industry Standards

• The company is comparing the results of Annamycin to historical data on HiDAC, a standard treatment for AML.
• The company notes that Annamycin has already demonstrated more than double the CR rate compared to historical data on HiDAC.
• The company is using a double-blind, placebo-controlled design, which is a standard approach in clinical trials.
• The company is also using an adaptive design, which is becoming more common in clinical trials to optimize the dose and improve the chances of success.
• The company is also addressing the issue of lifetime maximum allowable dose for anthracyclines, which is a common limitation in cancer treatment.

Stakeholder Impact

• Shareholders are likely to view this announcement positively due to the advancement of Annamycin to a Phase 3 trial.
• Patients with relapsed or refractory AML may benefit from this new treatment option.
• The company's employees are likely to be motivated by the progress of the clinical program.

Next Steps

• The company will begin contracting with MIRACLE trial sites in the second half of 2024.
• The first subject is planned to be treated in the MIRACLE trial in Q1 2025.
• Interim data will be unblinded and the optimal dose will be set in mid-2026.
• Enrollment of 3rd line subjects in MIRACLE2 will begin in 2026.
• Enrollment will end for 2nd line subjects in 2027.
• Final data for 2nd line subjects in MIRACLE will be available in 2028.
• The company plans to begin submission of a new drug application (NDA) in the second half of 2028.

Key Dates

Keywords

Annamycin, AML, Phase 3 trial, FDA, MIRACLE trial, Cytarabine, Relapsed, Refractory, Accelerated approval, Oncology, Hematologic Malignancies